
Opinion|Videos|October 14, 2024
Integrating HER2-Directed Therapies Into Standard Care for NSCLC
Key Takeaways
- HER2-directed therapies offer clinical, operational, and economic benefits in NSCLC management within managed care settings.
- NSCLC patients with HER2 mutations are the primary beneficiaries of HER2-directed therapies, necessitating precise identification.
Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Examine the clinical, operational, and economic implications of incorporating HER2-directed therapies into NSCLC management strategies within managed care settings.
- Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection?
Advertisement
Related to this article

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
3
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
4
Menopause Benefit Design Should Prioritize Access, Total Cost of Care
5


